Gelteq’s latest preclinical study, conducted in Melbourne, shows its proprietary oral gel platform increases cannabidiol absorption by more than 22% compared with a leading FDA‑approved oil‑based product, while delivering a higher peak exposure at a lower CBD concentration.
The enhanced bioavailability suggests the gel could offer a safer, more predictable, and easier‑to‑use alternative to conventional CBD oils and vapes, potentially allowing therapeutic effects at lower doses and reducing exposure to excipients and side effects.
The company’s market capitalization sits at roughly AUD 8.6 million, and it continues to post net losses with a margin of –3,950 % and liquidity ratios below 0.3, indicating ongoing financial headwinds that could limit rapid commercialization.
CEO John Smith said the results represent a “meaningful step forward for patients who rely on medicinal cannabis for therapeutic outcomes,” underscoring the patient‑centric focus of the platform.
While the study has not yet triggered a measurable market reaction, the company’s prior December 5 preclinical announcement saw a 5.8 % rise in investor interest, driven by a 300 % first‑hour bioavailability improvement; the current announcement is expected to reinforce confidence in Gelteq’s technology pipeline.
Gelteq plans to leverage the Special Access Scheme in Australia to accelerate market entry, and it is pursuing licensing, white‑label manufacturing, and co‑development agreements with medicinal cannabis producers, positioning the company to generate early revenues once regulatory approval is secured.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.